The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final phase II safety and efficacy results of study MC0452: Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma.
J. R. Merchan
No relevant relationships to disclose
H. C. Pitot
No relevant relationships to disclose
R. Qin
No relevant relationships to disclose
G. Liu
No relevant relationships to disclose
T. R. Fitch
No relevant relationships to disclose
W. J. Maples
No relevant relationships to disclose
J. Picus
Consultant or Advisory Role - Genentech
Research Funding - Wyeth
C. Erlichman
No relevant relationships to disclose